Avricore Health Inc V.AVCR

Q3 results

[lscfa]

 

Qtr ending	Deployed	Lease & service	Products sold	Revenue	Gross Profit	Margin
Q3 24	784	596,075	599,047	1,195,122	434,791	36.4%
Q2 24	781	581,166	464,040	1,045,206	370,775	35.5%
Q1 24	775	563,487	560,820	1,124,307	484,791	43.1%
Q4 23	693	475,579	878,824	1,354,403	501,466	37.0%
Q3 23	635	406,119	547,335	953,454	261,778	27.5%
Q2 23	541	387,206	160,843	548,049	229,471	41.9%
Q1 23	532	311,001	318,240	629,241	210,681	33.5%
Q4 22	416	140,685	836,550	977,235	168,845	17.3%
Q3 22	166	52,290	519,938	572,228	215,961	37.7%
Q2 22	53	14,940	161,235	176,175	56,874	32.3%
Q1 22	53	14,491	28,245	42,736	15,113	35.4%

[lscfa]

"Because the Company expects devices to be redeployed to new locations in Canada and the UK, management estimates that the Company will not require investment in new devices for the next 12 to 18 months. It also expects cash-on-hand, expected future cash inflows from revenues, and cash savings from redeployment of devices estimated to be sufficient to finance working capital for the next 12

[winnerswing]

Net QTR loss because of north of 300k$ share compensation. Cie would have been profitable without that. This compensation has never been as high as that in the last 7-8 Qtrs. 

[lscfa]

SBC is periodic and non-cash. Co. has positive cash flow from ops...   Qtr ending SBC Net income (loss) Cfo Q3 24 338,089 (179,015) 274,806 Q2 24 1,598 54,022

[lscfa]

Expanded table   Qtr ending SBC Net income (loss) CFO Q3 24 338,089 (179,015) 274,806 Q2 24 1,598 54,022 145,038 Q1 24